Equities Analysts Issue Forecasts for CervoMed Q3 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Roth Capital cut their Q3 2025 earnings estimates for CervoMed in a research report issued on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.76) per share for the quarter, down from their previous forecast of ($0.50). Roth Capital has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.

CRVO has been the subject of several other reports. Chardan Capital reiterated a “buy” rating and set a $15.00 price objective on shares of CervoMed in a research note on Monday, August 11th. Canaccord Genuity Group upped their target price on shares of CervoMed from $21.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Finally, D. Boral Capital upped their target price on shares of CervoMed from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.43.

CervoMed Stock Down 0.7%

CRVO opened at $10.12 on Thursday. CervoMed has a 52-week low of $1.80 and a 52-week high of $20.63. The company has a 50 day moving average of $7.74 and a two-hundred day moving average of $7.16. The company has a market cap of $93.61 million, a P/E ratio of -3.88 and a beta of -0.79.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.13). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%. The business had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $1.45 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers raised its holdings in CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after acquiring an additional 1,526 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in CervoMed by 251.8% in the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock valued at $34,000 after acquiring an additional 10,352 shares in the last quarter. HighTower Advisors LLC acquired a new stake in CervoMed in the first quarter valued at $104,000. Marshall Wace LLP acquired a new stake in CervoMed in the second quarter valued at $76,000. Finally, Bank of New York Mellon Corp acquired a new stake in CervoMed in the first quarter valued at $110,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.